Affymax, Inc. (NASDAQ:AFFY) is scheduled to speak at the 28th Annual JP Morgan Healthcare Conference on Wednesday, January 13. Representing the company will be its President and Chief Executive Officer Arlene Morris. Morris will begin the presentation at 9:00 am PT that morning. A live webcast of the presentation will be broadcasted online at http://www.affymax.com/. The webcast will be on the investors section of the site. It will remain on the site as a replay for thirty days following the conclusion of the event.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Affymax, Inc. is a biopharmaceutical company developing peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The Company's product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a relatively small synthetic peptide-based erythropoiesis stimulating agent (ESA), which it is developing for the treatment of anemia patients with chronic renal failure. The Company is conducting Phase III clinical trials in patients suffering from chronic renal renal failure, on dialysis and not on dialysis (pre-dialysis). In August 2008, the Company and Takeda Pharmaceutical Company Limited (Takeda), agreed to suspend development of Hematide to treat chemotherapy induced anemia.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
